the annualized present value of the program cost would be $760 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $285 million for 90% utilization by pregnant women and $120 million for 10% utilization by pregnant women.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $12 million for a group B streptococci vaccine.

If a vaccine program were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $3,400. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is -$1,500 for 90% utilization by pregnant women and $20,000 for 10% utilization by pregnant women. A negative value represents a saving in costs in addition to a saving in QALYs.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.

If a vaccine program for group B streptococci were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the QALYs gained would be 33,000. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 6,200.

If a vaccine program for group B streptococci were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the health care costs saved would be $435 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $125 million.

If a vaccine program for group B streptococci were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the program cost would be $800 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $215 million.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $9 million for a group B streptococci vaccine.